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Sheeppox virus (SPPV) is a member of the Capripoxvirus (CaPV) genus of the Poxviridae family. Members of
this genus, which also include goatpox and lumpy skin disease viruses, cause economically significant disease
in sheep, goats, and cattle. A rapid diagnostic assay for CaPV would be useful for disease surveillance as well
as for detection of CaPV in clinical samples and for outbreak management. Here we describe a fluorogenic
probe hydrolysis (TaqMan) PCR assay designed for rapid detection of CaPV and tested on sheep experimen-
tally infected with a virulent strain of SPPV. This assay can detect SPPV in buffy coats, nasal swabs, oral swabs,
scabs, and skin lesions as well as in lung and lymph nodes collected at necropsy. This single-tube diagnostic
assay can be performed in 2 h or less and can detect viral DNA in preclinical, clinical, and postmortem
samples.
The Capripoxvirus (CaPV) genus of the Poxviridae family of
viruses comprises sheeppox (SPPV), goatpox (GTPV), and
lumpy skin disease (LSDV) viruses, which cause disease in
sheep, goats, and cattle, respectively. These viruses are consid-
ered reportable agents to the World Organization for Animal
Health due to their potential for significant economic impact.
Members of the CaPV genus are closely related, with genomic
identities ranging from 96% between viral species to 99%
between isolates of the same species (27). They have complete
open reading frame (ORF) colinearity (13, 26, 27) and are
indistinguishable via serological methods (14–16). CaPVs tend
to be host specific; however, incidences where SPPV and
GTPV have crossed species, into goats and sheep, respectively,
have been documented (8, 20).
Transmission of SPPV is thought to occur through exposure
to aerosols or respiratory droplets produced by acutely in-
fected animals or by direct or indirect contact with lesions or
oronasal secretions (8, 17). Virus can be detected in nasal
secretions of animals infected by aerosol or contact exposure
(17) as well as in lesions found in the upper and lower respi-
ratory tracts of infected animals (1c, 11). Transmission may
also occur through the dermis, after contact exposure with cuts
or abrasions (1c, 21, 22, 25), or via mechanical transmission by
arthropod vectors (19).
Clinical signs of SPPV infection include fever, anorexia,
depression, conjunctivitis, rhinitis, respiratory distress, gener-
alized skin lesions, and enlargement of lymph nodes (9, 22). A
transient viremia develops but may not be detectable through-
out the entire course of infection (14). Transient viremias have
also been described for cattle infected with LSDV (7, 28).
Internal lesions are often seen at necropsy, especially in the
lungs, although lesions in the trachea, rumen, tongue, kidney,
nasal turbinates, and reproductive organs have also been re-
ported (1c, 11, 14).
SPPV is endemic throughout much of Africa, southwest and
central Asia, and the Indian subcontinent (3, 4, 23). Young
animals are most susceptible, where mortality rates can be as
high as 50 to 70% (10, 12). Outbreaks are controlled by ring
vaccination, quarantine, and slaughter and may result in sub-
stantial economic losses due to mortality, reduced productivity,
and trade restrictions (6, 24; www.fao.org). Rapid identifica-
tion of CaPV is key to curtailing outbreaks before major eco-
nomic damage can be inflicted.
A rapid test for CaPV that can detect virus before the onset
of clinical disease would be invaluable for controlling or man-
aging outbreaks as well as for disease surveillance. Here we
describe a fluorogenic probe hydrolysis (TaqMan) PCR assay
designed for rapid detection of CaPV and tested on sheep
experimentally infected with a virulent strain of SPPV. This
single-tube assay can be performed in 2 h or less and can detect
viral DNA prior to the onset of clinical disease.
MATERIALS AND METHODS
Viruses and cell cultures. The pathogenic field isolate SPPV strain A (SPPV-
SA) was obtained from a sick sheep in the Almatinskaya region of Kazakhstan
and passaged nine times in sheep at the Scientific Research Agricultural Insti-
tute, Kazakhstan (1987) (27). The pathogenic virus SPPV_RvKLP (RvKLP) was
derived from SPPV-SA as previously described (2). Primary lamb testis (LT) cell
cultures were obtained from the Animal and Plant Health Inspection Service
(APHIS), U.S. Department of Agriculture, Plum Island Animal Disease Center,
Greenport, NY.
Animal infections. Merino lambs (3 to 4 months old) were inoculated intra-
nasally with SPPV-SA (n  3) or RvKLP (n  5) at 106 PFU. Clinical signs of
* Corresponding author. Mailing address: Plum Island Animal Dis-
ease Center, P.O. Box 848, Greenport, NY 11944-0848. Phone: (631)
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SPPV infection, including fever (a rectal temperature of 39.7°C), anorexia,
lethargy, conjunctivitis, coughing, sneezing, nasal discharge, respiratory distress,
recumbency, and appearance of skin lesions, were monitored daily. Nasal swabs,
oral swabs, and conjunctival swabs were collected every day for the first 10 days
of the experiment and every other day thereafter for the duration of the 30-day
experiment. Scrapings of pox scabs were collected as they appeared. Clinical
samples were collected into tubes containing Dulbecco’s modified Eagle’s me-
dium (Invitrogen, San Diego, CA) with 50 g of gentamicin/ml (Invitrogen, San
Diego, CA) and stored at70°C until use. Blood samples were collected into BD
Vacutainer cell preparation tubes with sodium heparin (BD, Franklin Lakes,
NJ). Buffy coats were separated by centrifugation in a swinging rotor at 1,500
rpm (800  g), collected, spun down, resuspended in phosphate-buffered saline,
and stored at 4°C until use. Lambs were euthanized when they were moribund or
at the end of the 30-day experiment. Tissue samples were collected for virus
isolation (VI) or DNA extraction. Tissues collected at necropsy were immedi-
ately frozen at 70°C until use.
Virus isolation. Isolation of SPPV in clinical or necropsy samples was per-
formed on LT cells as described in World Organization for Animal Health
protocols (22). Nasal or buccal swabs, sonicated buffy coat samples, or homog-
enized tissue samples were filtered through a 0.45-m Spin-X filter (Costar,
Corning, NY), and 200 l of sample was used to infect LT cells in 24-well plates
in duplicate with negative controls. Cells were examined for cytopathic effect
(CPE) for 14 days after infection. The contents of negative wells were collected
and freeze-thawed, and the supernatant was sonicated and spun down. Samples
were then used to infect fresh LT cells, which were examined for another 14 days
postinfection (p.i.) for CPE. Samples that had no CPE after the second passage
were considered VI negative.
DNA extraction. DNAs were extracted from 200 l of cell culture supernatant,
transport medium containing nasal or buccal swabs, buffy coat samples, or ho-
mogenized tissue samples by using a DNeasy blood mini kit (Qiagen, Stanford,
CA) and were eluted in 100 l of AE buffer according to the manufacturer’s
instructions. DNA from purified virus was extracted as previously described (29).
Real-time PCR assay for SPPV. Reagents from an EZ-RT PCR kit (Applied
Biosystems, Branchburg, NJ) were used to prepare the reaction mix according to
the manufacturer’s guidelines. The final 25-l assay mix contained EZ buffer
solution, 5 mM manganese acetate, a 0.2 mM deoxynucleoside triphosphate mix,
and 0.1 U of recombinant rTth DNA polymerase. A forward primer (5 GGCG
ATGTCCATTCCCTG 3) (200 nM), reverse primer (5 AGCATTTCATTTC
CGTGAGGA 3) (500 nM), and fluorogenic minor groove-binding TaqMan
probe (5 CAATGGGTAAAAGATTTCTA 3; labeled with 6-carboxyfluores-
cein and a nonfluorescent quencher) (200 nM) were included in each reaction
mix. Sample template (2.5 l) was added to the reaction mix in a SmartCycler
(Cepheid, Sunnyvale, CA) 25-l reaction tube. Cycling conditions consisted of an
initial denaturation at 95°C for 120 seconds, followed by 45 amplification cycles
(95°C for 2 s and 60°C for 60 s). The assay was run on a Cepheid SmartCycler
(Cepheid, Inc., Sunnyvale, CA). Positive and negative controls were included
with each set of reaction mixtures.
PCR detection. All virus samples used to assess assay specificity were first
tested using virus-specific primers to verify the presence of viral nucleic acid (not
shown). Clinical samples for which there were conflicting data between VI and
real-time PCR were retested by conventional PCR using the KS-1.5 and KS1.6
forward and reverse primers, as previously described (18).
Statistical analysis. The performance of the CaPV real-time PCR assay was
compared to that of virus isolation and/or conventional PCR detection in clinical
and necropsy samples by using the disease/test relation calculators available at
the University of Oklahoma Health Sciences Center website (http://www
.fammed.ouhsc.edu/robhamm/cdmcalc.htm). The screening and diagnostic tests/
validity measures option in the Describe program of WINPEPI (http://www
.brixtonhealth.com) was utilized to calculate real-time PCR cutoff values.
RESULTS AND DISCUSSION
Assay design and optimization. Complete sequences avail-
able for the genomes of eight CaPVs were used for primer and
probe selection (13, 26, 27). These sequences included three
strains of SPPV (SPPV-SA, SPPV_Turky, and SPPV_Niskhi),
two strains of GTPV (GTPV_Pellor and GTPV_G20-LKV), and
three strains of LSDV (LSDV_Neethling 2490, LSDV_Neethling
Warmbaths, and LSDV_Neethling vaccine). Additionally, a par-
tial sequence was available for the KS-1 strain of SPPV (5).
Primers and probes were selected using ABI Prism Primer Ex-
press primer design software (Applied Biosystems, Foster City,
CA) from central regions of the genome (ORFs 24 though 123),
where the least genomic variability was observed (26, 27). Primer-
probe sets were searched against the NCBI nucleotide database
and selected based on 100% nucleotide identity to all members of
the CaPV genus. The target region falls within ORF 068 [poly(A)
polymerase (small subunit) gene]. Although this gene is present in
other poxviruses, only members of the CaPV genus were detect-
able with the selected primer-probe system (see below).
Assay analytical sensitivity and specificity. The analytical
sensitivity of the CaPV real-time PCR assay was determined
based on viral DNA extracted from purified SPPV-SA grown
in LK cells. Virus was diluted in log10 steps in Dulbecco’s
modified Eagle’s medium, and DNA was extracted and tested
by real-time PCR to determine the limit of detection. Sensi-
tivity was based on four independent experiments. After ad-
justment for extraction (100 l) and sample (2.5 l) volume,
the sensitivity of the assay ranged between 1.6 and 15.8 50%
tissue culture infective doses of SPPV. The efficiency of am-
plification [10(1/slope)] was 1.99, with an R2 value of 0.99 (Fig.
1), indicating an approximate doubling of product after each
cycle. In four independent experiments, the mean standard
deviation was determined to be 1.0 cycle threshold (CT) among
all dilutions.
The specificity of the CaPV real-time assay was determined
for members of the CaPV genus. DNAs were extracted from
five strains of SPPV, two strains of GTPV, and four strains of
LSDV and tested by real-time PCR (Table 1). All samples
were positive, with CT values ranging from 16 to 23. Members
of the Orthopoxvirus, Parapoxvirus, and Suipoxvirus genera of
the Poxviridae tested negative by the CaPV real-time PCR
assay (Table 1).
Agents included in differential diagnosis of CaPV as well as
samples of other viral vesicular diseases affecting sheep, goats,
or cattle were obtained from the Foreign Animal Disease Di-
agnostic Laboratory (FADDL), APHIS (U.S. Department of
Agriculture, Plum Island Animal Disease Center, Greenport,
NY), and tested using virus-specific primers in order to verify
the presence of viral nucleic acid. Samples were then examined
using the CaPV real-time assay. Bovine herpesvirus 2, blue-
tongue virus, rinderpest virus, peste des petits ruminants virus,
FIG. 1. Sensitivity of the CaPV real-time PCR assay, calculated
using SPPV samples obtained from infected cell culture supernatants
and run in quadruplicate. An inverse linear relationship exists between
CT values and log10 50% tissue culture infective dose (TCID50)/ml of
virus in the samples. The efficiency of amplification was 1.99, with an
R2 value of 0.99, indicating an approximate doubling of product after
each cycle.
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foot-and-mouth disease virus, and vesicular stomatitis virus all
tested negative by the CaPV real-time PCR assay (not shown).
Determination of cycle cutoff values. The optimum cutoff
value for the real-time PCR assay was determined using clin-
ical samples (buffy coats and nasal swabs) collected from eight
SPPV-inoculated animals and tested by real-time PCR and VI,
with conventional PCR used as a confirmatory test (18). The
Describe program of the WINPEPI statistical analysis program
was used to calculate an optimum cutoff value of 45.7 cycles.
Further analysis showed that while increasing the cutoff value
to 50 cycles resulted in a sensitivity of 100% for both sample
types, there was a resulting loss of specificity (90% buffy coats
and 80% nasal swabs) due to the appearance of false-positive
results. All subsequent results were based on a cutoff value of
45 cycles.
Assay clinical sensitivity and specificity. Infected lambs de-
veloped signs of clinical disease, including fever, loss of appe-
tite, depression, conjunctivitis, and nasal discharge. All lambs
developed fever by day 5 p.i. Lesions developed by day 7 and
began to scab over by day 14 p.i. All lambs developed neutral-
izing antibodies by day 14, and all but one lamb were eutha-
nized by day 21 or when they were found moribund. There was
no significant difference in disease onset or severity between
animals inoculated with the SPPV-SA and RvKLP viruses.
Oral swabs, conjunctival swabs, nasal swabs, buffy coats, and
lesion scabs were evaluated as clinical samples for early SPPV
detection. Oral and conjunctival swabs were not considered
good candidates for early detection of SPPV, since positive
results were not obtained until after the onset of clinical signs
(not shown). Nasal swabs were found to be positive by real-
time PCR starting on day 2 p.i., with all samples being positive
by day 4 (Fig. 2). The real-time assay was able to detect viral
DNA in nasal swabs 1 to 5 days prior to the onset of clinical
disease, as defined by fever (temperature of 39.7°C) and the
presence of skin lesions, and up to 2 days before VI-positive
results were seen. Virus was detected in nasal secretions of
infected animals until the day of death or day 20 for the one
surviving animal. The clinical sensitivity for the real-time assay
on nasal swabs was 100%, with a specificity of 95.2% (Table 2).
In buffy coat samples, virus was first detected by the CaPV
real-time assay on day 3, 1 to 3 days prior to the onset of
clinical disease. However, comparison to VI results showed a
few instances (4/42 samples) where samples were positive by
VI but negative by real-time PCR. The VI results were con-
firmed by conventional PCR, indicating that for buffy coat
samples, VI was more sensitive than real-time PCR (Table 2).
This may reflect the presence of inhibitors in blood or the
relatively low viremias associated with SPPV infections. Virus
was not detected in buffy coat samples by real-time PCR or VI
after day 12, even though virus was present in nasal secretions
of infected animals until day 20.
Scabs from pox lesions collected throughout the course of
the experiment and skin lesion samples collected at necropsy
were tested by VI and real-time PCR. Skin samples taken from
noninfected lambs and scabs collected from sheep, goats, and
cows infected with parapoxvirus (provided by APHIS/
FADDL) were used as negative controls. The results showed a
clinical sensitivity of 95.5% and a specificity of 100% (Table 2).
We tested the ability of our assay to detect SPPV in various
tissues obtained from acutely infected sheep during postmor-
tem examination. The CaPV real-time assay was able to detect
virus in the lungs, perilumbar lymph nodes, and pharyngeal
tonsils of all eight lambs tested.
The clinical sensitivity presented here was determined by
utilizing a limited number of experimentally inoculated ani-
mals. Further validation of this test will require larger numbers
of both infected and noninfected animals, ideally in a natural
setting.
TABLE 1. CaPVs and other poxviruses tested by the CaPV real-time PCR assaya
Genus Virus Strain Species oforigin 6-Carboxyfluorescein CT
Reference or
source
Capripoxvirus SPPV Almatinskaya (SA) Sheep 16.27 27
SPPV Turkey Sheep 19.88 27
SPPV Niskhi Sheep 22.32 27
SPPV Kenya Sheep 17.28 USDA, FADDL
SPPV Romania Sheep 19.6 USDA, FADDL
GTPV Pellor Goat 22.48 27
GTPV Israel Goat 18.26 USDA, FADDL
LSDV Makhana Cow 24.4 USDA, FADDL
LSDV Neethling Cow 23.28 26
LSDV Ismalia Cow 16.22 USDA, FADDL
LSDV Cameroon Cow 18.58 USDA, FADDL
Parapoxvirus Orf virus Oregon Goat 0 USDA, FADDL
Orf virus Virginia Goat 0 USDA, FADDL
Orf virus Indiana Goat 0 USDA, FADDL
Bovine papular stomatitis
virus
Kansas Cow 0 USDA, FADDL
Bovine papular stomatitis
virus
California Cow 0 USDA, FADDL
Orthopoxvirus Vaccinia virus Western Reserve NA 0
Camelpox virus Mangistauskiy Camel 0 1b
Horsepox virus Mongolia Horse 0 26
Suipoxvirus Swinepox virus Nebraska Pig 0 1a
a Samples were first tested by PCR or reverse transcription-PCR, using virus-specific primers, and then by real-time PCR using the CaPV real-time assay. Positive
(SA) and no-template controls were included with each set of reactions.
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Here we describe a TaqMan-based assay designed to detect
CaPV in sheep, goats, and cattle and tested on lambs experi-
mentally infected with SPPV (the type species of the genus
CaPV). As designed, this assay was capable of detecting LSDV
and GTPV in tissue culture samples. However, the clinical
effectiveness of this assay for LSDV in cattle and GTPV in
goats remains to be determined. Further validation of this
assay under field conditions will be necessary to ascertain its
viability as a diagnostic tool.
The CaPV real-time PCR assay provides a rapid, sensitive
test for CaPV that is able to detect SPPV prior to the onset of
clinical disease. For preclinical detection of SPPV, the sample
of choice was nasal swabs, which provided better sensitivity
than buffy coat samples. For clinical identification of SPPV,
scabs or skin lesion biopsies provided high sensitivity and spec-
ificity and were easy to collect without the need for euthanizing
suspect animals. Postmortem samples included those most
likely to be submitted for diagnosis, i.e., lung and regional
lymph nodes. These are all likely samples to be submitted for
testing during a field investigation.
In conclusion, our results indicate that the CaPV real-time
PCR assay is comparable to or exceeds the established method
of VI for preclinical detection of SPPV in sheep. Based on our
preliminary results, this assay should also be a useful tool for
FIG. 2. Detection of SPPV in nasal secretions of lambs at 0 to 8 days postinoculation. Bars represent body temperature (°C), and the solid
horizontal line indicates the cutoff temperature of 39.7°C, above which lambs were considered febrile. Arrows indicate the first day that clinical
signs were evident. Empty bars represent samples that were negative both by real-time PCR and VI. Hatched bars represent samples that were
positive by real-time PCR but negative by VI. Filled bars represent samples that were positive by both real-time PCR and VI.
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early detection and control of infections by other CaPV vi-
ruses, including GTPV and LSDV. This assay can differentiate
between CaPV and other viruses causing vesicular disease in
ruminants and has a high sensitivity in clinical samples. The
CaPV real-time PCR assay represents a significant improve-
ment over other established methods of CaPV detection due to
its speed, simplicity, and ability to be carried out in laboratories
without the need for tissue culture facilities.
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TABLE 2. Performance of CaPV real-time PCR assay compared
with VI or PCR detection with buffy coats, nasal swabs, and
lesion biopsies/scabs
Sample type and parameter
% of samples with
evaluated result (no. of
samples with evaluated
result/total no. of
samples tested)
95% Confidence
interval
Nasal swab
Sensitivitya 100.0 (51/51) 100.0–100.0
Specificityb 95.2 (20/21) 86.1–104.3
False-positive ratec 4.8 (1/21) 0.0–13.9
False-negative rated 0.0 (0/51) 0.0–0.0
Positive predictive valuee 98.1 (51/52) 94.3–101.8
Negative predictive valuef 100.0 (20/20) 100.0–100.0
Overall accuracyg 98.6 (71/72) 95.9–101.3
Buffy coat
Sensitivitya 90.5 (38/42) 81.6–99.4
Specificityb 96.7 (29/30) 90.2–103.1
False-positive ratec 3.3 (1/30) 0.0–9.8
False-negative rated 9.5 (4/42) 0.6–19.5
Positive predictive valuee 97.4 (38/39) 92.5–102.4
Negative predictive valuef 87.9 (29/33) 76.7–99.0
Overall accuracyg 93.1 (67/72) 87.2–98.9
Skin lesion/scab
Sensitivitya 95.5 (21/22) 86.8–104.2
Specificityb 100.0 (17/17) 100.0–100.0
False-positive ratec 0.0 (0/17) 0.0–0.0
False-negative rated 4.6 (1/22) 4.2–22.8
Positive predictive valuee 100.0 (21/21) 100.0–100.0
Negative predictive valuef 94.4 (17/18) 83.9–105.0
Overall accuracyg 97.4 (25/26) 92.5–102.4
a Number of PCR-positive samples/number of VI-positive samples.
b Number of PCR-negative samples/number of VI-negative samples.
c Number of PCR-positive samples confirmed to be negative/number of truly
positive samples.
d Number of PCR-negative samples confirmed to be negative/number of truly
positive samples.
e Number of samples that were PCR positive and had SPPV.
f Number of samples that were PCR negative and did not have SPPV.
g Total number of truly positive and truly negative samples/total number of
samples.
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